Search for a funded project
Inborn errors of immunity underlying life-threatening COVID-19 in previously healthy patients – GENCOVID
In December 2019, a pneumonia due to a novel coronavirus (SARS-CoV-2) emerged in the city of Wuhan, China [...] ranging from asymptomatic infection to lethal coronavirus infectious disease-19 (COVID-19). Two groups
Identification of early biomarkers of the response to corticosteroid therapy in COVID-19 patients. – CortiCoV
SARS-CoV-2 is the human coronavirus that caused the pandemic that began in Wuhan, China at the end of
duration of the restrictions to limit the spread of coronavirus, but also during and after the loosening of
response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the lung can lead to life-
The role of the Army in the "war" against the coronavirus and its perception by the population – ARMY
on of the military in the fight against the coronavirus, designated as an "invisible enemy". The objective
Structural and functional outcomes of epitranscriptomic methylation of (+)RNA virus genomes – VIRAGE
For selected viruses, here Flaviviruses and Coronaviruses, using our preliminary data and experimental
Involvement of circulating fibrocytes in pathophysiology and prognosis of COVID-19 pneumonia – FIBROCO
High circulating levels of fibrocytes are correlated to an unfavourable outcome during acute respiratory distress syndrome (ARDS) and idiopathic pulmonary fibrosis. COVID-19 pneumonia shares common histological and inflammatory features with ARDS. We aimed to determine the involvement of circulating fibrocytes during the course of COVID-19 pneumonia, and to assess if fibrocytes could be a prognosis biomarker.
Endothelial damage and coagulation activation at the lung microvascular level may play an important role in the physiopathology of the COVID-19 ARDS. The project aims to prospectively investigate both bedside pulmonary physiological markers (mainly alveolar dead-space) and biological markers of coagulopathy and endothelial dysfunction in COVID-19 and non-COVID-19 ARDS patients.
Early identification of risk associated with drugs used in COVID-19: analysis of global pharmacovigilance data – Vigi-Drugs COVID-19
Early Identification of Drug Risk in COVID-19: Analysis of Global Pharmacovigilance Data
Participatory action research on the residential, educational and food insecurities of exiled people during the health crisis in Rennes.